Disease Focus: Blood Cancer
Late Stage Pre-Clinical Development of a Cirmtuzumab Based CAR T-cell for the Treatment of ROR1+ Hematological Malignancies
Therapeutic Candidate or Device We are developing ROR1 Chimeric Antigen Receptor (CAR) modified T-cells for the treatment of hematological and solid tumor cancers. Indication The target for our therapy are patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). Therapeutic Mechanism Our lead candidate ROR1 CAR-T cell therapy modifies […]
Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia
Therapeutic Candidate or Device CLT030-ADC, a novel drug targeting a leukemic stem cell surface protein CLL1, is intended to improve therapeutic outcome for AML patients. Indication CLT030-ADC is intended to improve remission rates in AML patients. Therapeutic Mechanism CLT030-ADC is an antibody-drug conjugate targeting leukemic stem cell surface protein CLL1. Leukemic stem cells (LSC) are […]
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy
Therapeutic Candidate or Device CD34+ Cord-Blood Derived Hematopoietic Stem and Progenitor Cells Co-Cultured and Co-Infused with Genetically Modified Endothelial Cells Indication Life-threatening high-risk hematologic malignancies including leukemia and lymphoma Therapeutic Mechanism Appropriately matched cord-blood derived stem and progenitor cells which has a significant population of both short- and long-term stem cells (expanded by genetically modified […]
Stem Cell Therapies for Leukemia: Marching Toward the Clinic
On March 25th, 2014, California’s Stem Cell Agency (CIRM) hosted a live Google Hangout about recent progress in stem cell based treatment strategies for leukemia. Guest experts included CIRM grantees Dr. Catriona Jamieson of UCSD and Ravi Majeti of Stanford University who discussed their CIRM-funded research projects which aim to bring stem cell based therapies […]
Anica Sayoc, City of Hope – CIRM Stem Cell #SciencePitch
Catriona Jamieson, UCSD – CIRM Stem Cell #SciencePitch
Irving Weissman, Stanford – CIRM Stem Cell #SciencePitch
Leukemia: Advancing Stem Cell Therapies – 2011 CIRM Grantee Meeting
Daniel Goff speaks at the 2011 CIRM Grantee Meeting about identifying potential leukemia drugs that could zero-in on and kill the cancer stems cells that are thought to be responsible for relapse after chemotherapy treatment. Goff is a CIRM Scholar and PhD student at UC San Diego.
Spotlight on Basic Research: Irv Weissman
Irv Weissman, Ph.D., spoke at the “Spotlight on Basic Research,” an educational event presented at the CIRM Governing Board meeting on August 20, 2009. Weissman has a CIRM Comprehensive grant to identify cell surface markers on human embryonic stem cells that distinguish differentiated cells from potentially tumorigenic cells. He also has a CIRM Disease Team […]
Spotlight on Leukemia: Welcoming Remarks
Robert Klein, J.D. and David Brenner, M.D., gave the welcoming remarks for the “Spotlight on Leukemia,” an educational event presented at the CIRM Governing Board meeting on June 18, 2009. Klein is Chair of the CIRM Governing Board and President of Klein Financial Corporation. Brenner is vice chancellor for health sciences and dean at the […]